Clinical microbiology has experienced an unprecedented wave of innovation due to the introduction of advanced testing such as PCR, MALDI-TOF, and PNA-FISH.  The wave of new technologies has dramatically improved the time to pathogen identification result from culture, but has not impacted antimicrobial susceptibility testing: the definitive diagnostic result for changing antibiotic therapy in patients with bloodstream infections.  This presentation explores the clinical need for faster phenotypic susceptibility testing using the Accelerate PhenoTest™ BC kit.  Topics covered include the benefits to the patient and the economic benefits to the healthcare institution.